Related Experiment Video
Updated: May 15, 2026
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
Antiplatelet therapy after coronary stenting
Benjamin Z Galper1, Laura Mauri
1Center for Clinical Biometrics, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.
Insights
The optimal duration of dual antiplatelet therapy (DAPT) after coronary stent placement remains unknown. Current guidelines suggest 1-12 months, but ongoing trials will clarify best practices for preventing myocardial infarction and stent thrombosis.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Dual antiplatelet therapy (DAPT) is crucial after percutaneous coronary intervention (PCI) for preventing myocardial infarction, death, and stent thrombosis.
- Current guidelines recommend DAPT for 1 month after bare metal stents (BMS) and 6-12 months after drug-eluting stents (DES), but evidence is conflicting.
- Stent thrombosis rates are declining due to improved techniques and stent design, yet optimal DAPT duration is undetermined.
Purpose of the Study:
- To review the current evidence and ongoing research regarding the optimal duration of DAPT after coronary stent placement.
- To discuss the balance between preventing ischemic events (myocardial infarction, stent thrombosis) and managing bleeding risk associated with DAPT.
- To provide guidance on DAPT duration in the interim period before definitive trial results are available.
Main Methods:
- Review of existing literature, including randomized trials and guideline recommendations.
- Analysis of data concerning the efficacy of DAPT in preventing stent thrombosis and myocardial infarction.
- Evaluation of bleeding risks associated with extended DAPT durations.
Main Results:
- Conflicting data exist regarding the optimal DAPT duration post-PCI.
- Shorter durations (1 month for BMS) are generally accepted, while longer durations (6-12 months for DES) are debated.
- Smaller trials show increased bleeding with longer DAPT, but lack power to assess stent thrombosis or mortality benefits/risks definitively.
Conclusions:
- Optimal DAPT duration after coronary stent placement is not yet established.
- Extended DAPT may benefit high-risk patients but increases bleeding risk.
- Until large trials conclude, continuing DAPT for at least 6-12 months post-PCI is prudent for suitable patients.
Opinion Statement:
While dual antiplatelet therapy (DAPT), after percutaneous coronary intervention (PCI) has demonstrated benefit for two important cardiovascular indications, 1) prevention of future myocardial infarction and death following acute coronary syndromes and 2) prevention of stent thrombosis, the optimal duration of treatment with dual antiplatelet therapy after coronary stent placement is not known. While current guidelines have recommended treatment with dual antiplatelet therapy for between 1 month after receiving a bare metal stent (BMS) and 6 to 12 months after PCI with a drug eluting stent (DES), there are conflicting data to guide practice. Stent thrombosis is rare, and is declining over time following improvements in procedural technique and stent design, yet definitive data regarding the timing of safe discontinuation of dual antiplatelet therapy are not yet available. Furthermore, extended duration of antiplatelet therapy beyond 6-12 months may aid in the prevention of spontaneous MI and cardiac mortality, particularly in higher risk anatomic or clinical subgroups. Moderately sized randomized trials have recently demonstrated bleeding risk associated with longer durations of therapy, but these studies have been relatively limited in their power to exclude differences in rates of stent thrombosis, or clinically significant impact on the occurrence of myocardial infarction and death in this patient population. Large randomized trials powered to examine stent thrombosis, bleeding, and mortality and myocardial infarction, are underway that are expected to guide practice in the near future. Until that time it is most prudent to continue antiplatelet therapy for at least 6-12 months after coronary stent placement in suitable patients.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Angina IV: Management
01:26Atherosclerosis III: Management